Company news
Innate Pharma Sa Class A (EURONEXT:IPH) news
Every Innate Pharma Sa Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
September 10, 2026
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Innate Pharma : Announces Pricing of €30 million Offering of Ordinary Shares
August 14, 2026
Innate Pharma Announces Proposed Offering of Ordinary Shares
August 13, 2026
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
August 10, 2026
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
August 10, 2026
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
July 23, 2026
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Con...
July 21, 2026
Outcome of Innate Pharma’s 2026 Annual General Meeting
May 22, 2026
Innate Pharma to participate in the Jefferies Global Healthcare Conference
May 19, 2026
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
May 13, 2026
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
May 12, 2026
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
May 6, 2026
Innate Pharma to Participate in the D. Boral Capital Global Conference
April 23, 2026
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
April 17, 2026
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
April 13, 2026
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
April 13, 2026
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
April 8, 2026
Innate Pharma to Participate in the Kempen Life Sciences Conference
April 3, 2026
Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report
April 2, 2026
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
March 26, 2026
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
March 19, 2026
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
February 19, 2026
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
February 18, 2026
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
January 7, 2026
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
December 22, 2025
Innate Pharma Releases Its 2026 Financial Calendar
December 11, 2025
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
November 28, 2025
Innate Pharma to Present at Jefferies Global Healthcare Conference
November 17, 2025
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
November 13, 2025
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
November 10, 2025
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
November 5, 2025
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
October 14, 2025
Innate Pharma Reports First Half 2025 Business Update and Financial Results
September 17, 2025
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
September 15, 2025
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
September 10, 2025
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
September 2, 2025
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
August 4, 2025
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
July 29, 2025
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
July 4, 2025
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
June 17, 2025
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 E...
June 13, 2025
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
May 27, 2025
Outcome of Innate Pharma’s 2025 Annual General Meeting
May 23, 2025
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
May 23, 2025
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
May 19, 2025
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
May 15, 2025
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
May 13, 2025
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
May 12, 2025
Innate Pharma announces conference call and webcast for Q1 2025 business update
May 6, 2025